Nitrogen containing privileged structures and their solid phase combinatorial synthesis

Combinatorial Chemistry and High Throughput Screening

Volumn 16, Issue 5, 2013, Pages 345-393

  Verma, Amit ^a   Yadav, Mange Ram ^a   Giridhar, Rajani ^a   Prajapati, Navnit ^a   Tripathi, Avinash C ^b   Saraf, Shailendra K ^b  

^a M S UNIVERSITY OF BARODA   (India)

^b Faculty of Pharmacy   (India)

Author keywords

Benzodiazepine; Combinatorial synthesis; Cyclic peptides; Nitrogen heterocyclics; Privileged structures; Purines and pyrimidines; Solid phase synthesis

Indexed keywords

1,2,3,4 TETRAHYDROQUINOLINE DERIVATIVE; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 1,4 DIHYDROPYRIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BENZOXAZOLE DERIVATIVE; CYCLOPEPTIDE; DIHYDROPYRIDINE DERIVATIVE; INDOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; MOLECULAR SCAFFOLD; NITROGEN DERIVATIVE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PURINE DERIVATIVE; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; ROLIPRAM; TETRAHYDROISOQUINOLINE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANTHELMINTIC ACTIVITY; ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTIDIABETIC ACTIVITY; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIULCER ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; COMBINATORIAL LIBRARY; DRUG TRANSFORMATION; MOLECULAR INTERACTION; MOLECULAR RECOGNITION; MOLECULAR SIZE; PRIORITY JOURNAL; SOLID PHASE SYNTHESIS;

BENZODIAZEPINES; COMBINATORIAL CHEMISTRY TECHNIQUES; HETEROCYCLIC COMPOUNDS; MOLECULAR STRUCTURE; NITROGEN; PURINES; PYRIMIDINES; SOLID-PHASE SYNTHESIS TECHNIQUES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877971188     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207311316050003     Document Type: Article

References (241)

1. Stockwell, B. R. Exploring biology with small organic molecules. Nature, 2004, 432, 846-854.
2. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pomplinano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug. Discov., 2007, 6, 29-40.
3. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whiter, W. L.; Lundell, G. F; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lottie, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem., 1988, 31, 2235-2246.
4. Ripka, W. C.; De Lucca, G. V.; Bach, A. C.; Pottorf, R. S.; Blaney, J. M. Protein β-turn mimetics I. Design, synthesis, and evaluation in model cyclic peptides. Tetrahedron, 1993, 49, 3593-3608.
5. De Simone, R. W.; Currie, K. S.; Mitchell, S. A.; Darrow, J. W.; Pippin, D. A. Privileged structures: applications in drug discovery. Comb. Chem. High Throughput Screen., 2004, 7, 473-494.
6. Matthew, E. W.; Scott, A. S.; Brent, R. S. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol., 2010, 14, 347-361.
7. Ariens, E. J.; Beld, A. J.; Rodrigues de Miranda, J. F.; Simonis, A. M. The pharmacon-receptor-effector concept: a basis for understanding the transmission of information in biological systems. In O'Brien, R.D. (Ed.), The Receptors, A Comprehensive Treatise, Plenum Press, New York. 1979, 1, pp 33-91.
8. Andrews, P. R.; Lloyd, E. J. Molecular conformation and biological activity of central nervous system active drugs. Med. Res. Rev., 1982, 2, 355-393.
9. Bemis, G.; Murko, M. M. The Properties of Known Drugs. 1. Molecular Frameworks. J. Med. Chem., 1996, 39, 2887-2893.
10. Lowrie, J. F.; Delisle, R. K.; Hobbs, D. W.; Diller, D. J. The Different Strategies for Designing GPCR and Kinase Targeted Libraries. Comb. Chem. High. Through. Screen., 2004, 7, 495-510.
11. Horton, D. A.; Bourne, G. T.; Smythe, M. L. The Combinatorial Synthesis of Bicyclic Privileged Structures or Privileged Substructures. Chem. Rev., 2003, 103, 893-930.
12. Patchett, A. A.; Nargund, R. P. Privileged structures - an update. Ann. Rep. Med. Chem., 2000, 35, 289-298.
13. Muller, G. Medicinal chemistry of target family-directed masterkeys. Drug Discovery Today, 2003, 8, 681-691.
14. Poupaert, J.; Carato, P.; Colacillo, E. 2(3H)-benzoxazolone and bioisosters as "privileged scaffold" in the design of pharmacological probes. Curr. Med. Chem., 2005, 12, 877-885.
15. Luca, C.; Daniela, B. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem., 2006, 13, 65-85.
16. Veber, D. F.; Johnson, S. R.; Cheng, H-Y; Smith, B. R., Ward, K. W.; Kopple, K. D. Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. J. Med. Chem., 2002, 45, 2615- 2623.
17. Lewell, X. Q.; Judd, D. B.; Watson, S. P.; Hann, M. M. RECAP-retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J. Chem. Inf. Comput. Sci., 1998, 38, 511-522.
18. Hajduk, P. J.; Bures, M.; Praestgaard, J.; Fesik, S. W. Privileged Molecules for Protein Binding Identified from NMR-Based Screening. J. Med. Chem., 2000, 43, 3443-3447.
19. Bondensgaart, K.; Ankerson, M.; Thogersen, H.; Hansen, B. S.; Wulff, B. S.; Bywater, R. P. Recognition of Privileged Structures by G-Protein Coupled Receptors. J. Med. Chem., 2004, 47, 888- 899.
20. Tyndall, J. D. A.; Pfeiffer, B.; Abbenante, G.; Fairlie, D. P Over one hundred peptide-activated G protein-coupled receptors recognize ligands with turn structure. Chem. Rev., 2005, 105, 793- 826.
21. Bunin, B. A.; Ellman, J. A. Larger and more weakly coordinating anions: Nb(OTeF5)6- and Ti(OTeF5)62. J. Am. Chem. Soc., 1992, 114, 10997-10998.
22. De Witt, S. H.; Kiely, J. S.; Stankovic, C. J.; Schroeder, M. C.; Cody, D. M. R.; Pavia, M. R.. "Diversomers": An approach to nonpeptide, nonoligomeric chemical diversity. Proc. Natl. Acad. Sci. U. S. A., 1993, 90, 6909-6913.
23. Goff, D. A.; Zuckermann, R. N. Solid-phase synthesis of defined 1, 4- benzodiazepine-2, 5-dione mixtures. J. Org. Chem., 1995, 60, 5744-5745.
24. Mayer, J. P.; Zhang, J. W.; Bjergarde, K.; Lenz, D. M.;Gaudino, J. J. Solid phase synthesis of 1, 4-benzodiazepine-2, 5-diones. Tetrahedron Lett., 1996, 37, 8081-8084.
25. Hutchins, S. M.; Chapman, K. T. A general method for the solid phase synthesis of ureas. Tetrahedron Lett., 1994, 35, 4055-4058.
26. Beebe, X.; Schore, N. E.; Kurth, M. J. Research Article Polymersupported synthesis of 2, 5-disubstituted tetrahydrofurans. J. Am. Chem. Soc., 1992, 114, 10061-10062.
27. Pei, Y. H.; Moos, W. H. Post-modification of peptoid side chains: [3+2] cycloaddition of nitrile oxides with alkenes and alkynes on the solidphase. Tetrahedron Lett., 1994, 35, 5825-5828.
28. Yu, K.-L.; Deshpande, M. S.; Vyas, D. M. Heck reactions in solid phase synthesis. Tetrahedron Lett., 1994, 35, 8919-8922.
29. Deshpande, M. S. Formation of carbon-carbon bond on solid support: Application of the stille reaction. Tetrahedron Lett., 1994, 35, 5613- 5614.
30. Frenette, R.; Friesen, R. W. Biaryl synthesis via suzuki coupling on a solid support. Tetrahedron Lett., 1994, 35, 9177-9180.
31. Rano, T. A.; Chapman, K. T. Solid phase synthesis of aryl ethers via the mitsunobu reaction. Tetrahedron Lett., 1995, 36, 3789-3792.
32. Nicolaou, K. C.; Winssinger, N.; Pastor, J.; Ninkovic, S.; Sarabia, F.; He, Y.; Vourloumis, D.; Yang, Z.; Li, T.; Giannakakou, P.; Hamel, E. Synthesis of epothilones A and B in solid and solution phase. Nature, 1997, 387, 268-272.
33. Nicolaou, K. C.; Winssinger, N.; Vourloumis, D.; Ohshima, T.; Kim, S.; Pfefferkorn, J.; Xu, J.-Y.; Li, T. Solid and Solution Phase Synthesis and Biological Evaluation of Combinatorial Sarcodictyin Libraries. J. Am. Chem. Soc., 1998, 120, 10814-10826.
34. Watson, C. Polymer-Supported Synthesis of Non-Oligomeric Natural Products. Angew. Chem., Int. Ed., 1999, 38, 1903-1908.
35. Hall, D. G.; Manku, S.; Wang, F. Solution- and Solid-Phase Strategies for the Design, Synthesis, and Screening of Libraries Based on Natural Product Templates: A Comprehensive Survey. J. Comb. Chem., 2001, 3, 125-150.
36. Nicolaou, K. C.; Pfefferkorn, J. A. Solid phase synthesis of complex natural products and libraries thereof. Biopolymers, 2001, 60, 171-193.
37. Hanessian, S.; Yun, H.; Hou, Y.; Tintelnot-Blomley, M. Stereoselective Synthesis of Constrained Azacyclic Hydroxyethylene Isosteres as Aspartic Protease Inhibitors: Dipolar Cycloaddition and Related Methodologies toward Branched Pyrrolidine and Pyrrolidinone Carboxylic Acids. J. Org. Chem., 2005, 70, 6746-6756.
38. Iserloh, U.; Pan, J.; Stamford, A. W.; Kennedy, M. E.; Zhang, Q.; Zhang, L.; Parker, E. M.; McHugh, N. A.; Favreau, L.;Strickland, C.; Voit, J. Discovery of an orally efficaceous 4- phenoxypyrrolidine-based BACE-1 inhibitor. Bioorg. Med. Chem. Lett., 2008, 18, 418-422.
39. Washburn, D. G.; Hoang, T. H.; Frazee, J. S.; Johnson, L.; Hammond, M.; Manns, S.; Madauss, K. P.; Williams, S. P.; Duraiswami, C.; Tran, T. B.; Stewart, E. L.; Grygielko, E. T.; Glace, L. E.; Trizna, W.; Nagilla, R.; Bray, J. D.; Thompson, S. K. Bioorg. Med. Chem. Lett., 2009, 19, 4664-4668.
40. Jiang, W.; Tucci, F. C.; Tran, J. A.; Fleck, B. A.; Wen, J.; Markison, S.; Marinkovic, D.; Chen, C. W.; Arellano, M.; Hoare, S. R.; Johns, M.; Foster, A. C.; Saunders, J.; Chen, C. Pyrrolidinones as potent functional antagonists of the human melanocortin-4 receptor. Bioorg. Med. Chem. Lett., 2007, 17, 5610- 5613.
41. Gong, Y.; Becker, M.; Choi-Sledeski, Y. M.; Davis, R. S.; Salvono, J. M.; Chu, V.; Brown, K. D.; Pauls, H. W. Solid-phase parallel synthesis of azarene pyrrolidinones as factor Xa inhibitors. Bioorg. Med. Chem. Lett., 2000, 10, 1033-1036.
42. Choi-Sledeski, Y. M.; Mcgarry, D. G.; Green, D. M.; Mason, H. J.; Becker, M. R.; Davis, R. S.; Ewing, W. R.; Dankulich, W. P.; manetta, V. E.; Morris, R. L.; Spada, A. P.; Cheney, D. L.; Brown, K. D.; Colussi, D. J.; Chu, V.; Heran, C. L.; Morgan, S. R.; Bentley, R. G.; Leadley, R. J.; Maigan, S.; Guilloteau, J. P.; Dunwiddie, C. T.; Pauls, H. W. Sulfonamidopyrrolidinone Factor Xa Inhibitors: Potency and Selectivity Enhancements via P-1 and P-4 Optimization. J. Med. Chem., 1999, 42, 3572-3587.
43. Melamed, J. Y.; Egbertson, M. S.; Varga, S.; Vacca, J. P.; Moyer, G.; Gabryelski, L.; Felock, P. J.; Stillmock, K. A.; Witmer, M. V.; Schleif, W.; Hazuda, D. J.; Leonard, Y.; Jin, L.; Ellis, J. D.; young, S. D. Synthesis of 5-(1-H or 1-alkyl-5-oxopyrrolidin-3-yl)-8- hydroxy- [1, 6]-naphthyridine-7- carboxamide inhibitors of HIV-1 integrase. Bioorg. Med. Chem. Lett., 2008, 18, 5307-5310.
44. Davis, C. W. Assessment of selective inhibition of rat cerebral cortical calcium-independent and calcium-dependent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions. Biochim. Biophy. Acta., 1984, 797, 354-362.
45. Schwabe, U.; Miyake, M.; Ohga, Y.; Daly, J. W. 4-(3- Cyclopentyloxy-4- methoxyphenyl)-2-pyrrolidone (ZK 62711): a Potent Inhibitor of Adenosine Cyclic 3', 5'-Monophosphate Phosphodiesterases in Homogenates and Tissue Slices from Rat Brain. Mol. Pharmacol., 1976, 12, 900-910.
46. Nemoz, G.; Moueqqit, M.; Prigent, A.-F.; Pacheco, H. Isolation of similar rolipram-inhibitable cyclic-AMP-specific phosphodiesterases from rat brain and heart. Eur. J. Biochem., 1989, 184, 511-545.
47. Reeves, M. L.; Leigh, B. K.; England, P. J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem. J., 1987, 241, 535-541.
48. Beavo, J. A.; Reifmyder, D. H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharm. Sci., 1990, 11, 150-155.
49. Schneider, H. H.; Schmiechen, R.; Brezinaki, M.; Seidler, J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol., 1986, 127, 105-115.
50. Souness, J. E.; Scott, L. C. Stereospecificity of rolipram actions on eosinophil cyclic AMP-specific phosphodiesterase. Biochem. J., 1993, 291, 389-395.
51. Kaulen, P.; Brbing, G.; Schneider, H. H.; Sarter, M.; Baumgarten, H. G. Autoradiographic mapping of a selective cyclic adenosine monophosphate phosphodiesterase in rat brain with the antidepressant [3H]rolipram. Brain. Res., 1989, 503, 229-245.
52. Torphy, T. J.; Stadel, J. M.; Burman, M.; Cieelineki, L. B.; McLaughlin, M. M.; White, J. R.; Livi, G. P. Coexpression of human cAMP-specific phosphodiesterase activity and high affinity rolipram binding in yeast. J. Biol. Chem., 1992, 267, 1798-1804.
53. Wachtel, H. J. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3', 5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. Pharm. Pharmacol., 1983, 35, 440-444.
54. Schultz, J. E.; Schmidt, B. H. Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes betaadrenoceptor subsensitivity in rat cerebral cortex. Naunyn- Schmiedeberg's Arch Pharmacol., 1986, 333, 23-30.
55. Liu, Z.; Nefzi, A. Solid-Phase Synthesis of N-Substituted Pyrrolidinone Tethered N-substituted Piperidines via Ugi Reaction. J. Comb. Chem., 2010, 12, 566-570.
56. Pendri, A.; Troyer, T. L.; Sofia, M. J.; Walker, M. A.; Naidu, B. N.; Banville, J.; Meanwell, N. A.; Dicker, I.; Lin, Z.; Krystal, M.; Gerritz, S. W. Solid Phase Synthesis of Novel Pyrrolidinedione Analogs as Potent HIV-1 Integrase Inhibitors. J. Comb. Chem., 2010, 12, 84-90.
57. Sausins, A.; Duburs, G. Synthesis of 1, 4-dihydropyridines by cyclocondensation reactions. Heterocycles, 1988, 27, 269-289.
58. Gordecv, M. F.; Patel, D. V.; England, B. P.; Jonnalagadda, S.; Combs, J. D.; Gordon, E. M. Combinatorial synthesis and screening of a chemical library of 1, 4-dihydropyridine calcium channel blockers. Bioorg. Med. Chem., 1998, 6, 883-889.
59. Gordecv, M. F.; Patel, D. V.; Gordon, E. M. Approaches to combinatorial synthesis of heterocycles: A solid-phase synthesis of 1, 4-dihydropyridines. J. Org. Chem., 1996, 61, 924-928.
60. Schramm, M.; Thomas, G.; Towart, R.; Franckowiak, G. Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels. Nature, 1983, 303, 535-537.
61. Gordecv, M. F.; Patel, D. V.; Wu, J.; Gordon, E. M. Approaches to combinatorial synthesis of heterocycles: Solid phase synthesis of pyridines and pyrido [2, 3-d]pyrimidines. Tetrahedron Lett., 1996, 37, 4643-4646.
62. Ahn, H.-S.; Bercovici, A.; Boykow, G.; Bronnenkant, A.; Chackalamannil, S.; Chow, J.; Cleven, R.; Cook, J.; Czarniecki, M.; Domalski, C.; Fawzi, A.; Green, M.; Gundes, A.; Ho, G.; Laudicina, M.; Lindo, N.; Ma, K.; Manna, M.; McKittrick, B.; Mirzai, B.; Nechuta, T.; Neustadt, B.; Puchalski, C.; Pula, K.; Silverman, L.; Smith, E.; Stamford, A.; Tedesco, R. P.; Tsai, H.; Tulshian, D.; Vaccaro, H.; Watkins, R. W.; Weng, X.; Witkowski, J. T.; Xia, Y.; Zhang, H. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. J. Med. Chem., 1997, 40, 2196-2210.
63. Xia, Y.; Chackalamannil, S.; Czarniecki, M.; Tsai, H.; Vaccaro, H.; Cleven, R.; Cook, J.; Ahamad, F.; Watkins, R.; Zhang, H. Synthesis and evaluation of polycyclic pyrazolo [3, 4-d]pyrimidines as PDE1 and PDE5 cGMP phosphodiesterase inhibitors. J. Med. Chem., 1997, 40, 4372-4377.
64. Agarwal, A.; Srivastava, K.; Puri, S. K.; Chauhan, P. M. S. Synthesis of 2, 4, 6-trisubstituted pyrimidines as antimalarial agents. Bioorg. Med. Chem., 2005, 13 4645-4650.
65. Stocks, P. A.; Raynes, K. J.; Bray, P. G.; Park, B. K.; Neill, P. M.; Ward, S. A. Novel short chain chloroquine analogues retain activity against chloroquine resistant k1 plasmodium falciparum. J. Med. Chem., 2002, 45, 4975-4983.
66. Katiyar, S. B.; Bansal, I.; Saxena, J. K.; Chauhan, P. M. S. Syntheses of 2, 4, 6-trisubstituted pyrimidine derivatives as a new class of antifilarial topoisomerase II inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 47-50.
67. Ren, Q.; Cui, Z.; He, H.; Gu, Y. A facile synthesis and fungicidal activities of novel fluorine-containing pyrido [4, 3- d]pyrimidin-4(3H)-ones. J. Fluorine Chemistry, 2007, 128, 1369- 1375.
68. Eckhardt, W.; Huxdey, P. Fungicidal 5-substituted pyrimidine derivatives, compositions, and method of use therefor. Biotechnology Advances, 1988, 6, 339.
69. Ali, A.; Taylor, G. E.; Ellsworth, K.; Harris, G.; Painter, R.; Silver, L. L.; Young, K. Novel pyrazolo [3, 4-d]pyrimidine-based inhibitors of Staphylococcus aureus DNA polymerase III: design, synthesis, and biological evaluation. J. Med. Chem., 2003, 46, 1824-1830.
70. Gangjee, A.; Mavandadi, F.; Sherry, F.; Queener, S. F. Effect of N9-methylation and bridge atom variation on the activity of 5- substituted 2, 4-diaminopyrrolo [2, 3-d]pyrimidines against dihydrofolate reductases from Pneumocystis carinii and Toxoplasma gondii. J. Med. Chem., 1997, 40, 1173-1177.
71. Sunduru, N.; Agarwal, A.; Katiyar, S. B.; Goyal, N.; Gupta, S.; Chauhan, P. M. S. Synthesis of 2, 4, 6-trisubstituted pyrimidine and triazine heterocycles as antileishmanial agents. Bioorg. Med. Chem., 2006, 14, 7706-7715.
72. Torrence, P. F.; Xuesen, Fan-X.; Zhang, X.; Philippe, M.; Loiseau, P. M. Structurally diverse 5- substituted pyrimidine nucleosides as inhibitors of Leishmania donovani promastigotes in vitro. Bioorg. Med. Chem. Lett., 2006, 16, 5047-5051.
73. Ram, V. J. Chemotherapeutic agents, XXI: Synthesis of Pi-deficient pyrimidines as leishmanicides. Arch Pharm(Weinheim), 1991, 324, 837-839.
74. Baba, M.; De Clercq, E.; Tanaka, H.; Ubasawa, M.; Takashima, H.; Sekiya, K.; Nitta, I.; Umezu, K.; Walter, R. T.; Mori, S. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives. Mol. Pharmacol., 1991, 39, 805-810.
75. Tanaka, H.; Takashima, H.; Ubasawa, M.; Sekiya, K.; Nitta, I.; Baba, M.; Shigetak, S.; Walker, R. T.; De Clercq, E.; Miyasaka, T. Synthesis and antiviral activity of deoxy analogs of 1- [(2-hydroxyethoxy)methyl]-6- (phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem., 1992, 35, 4713-4719.
76. Mai, A.; Artico, M.; Sbardella, G.; Quartarone, S.; Massa, S.; Loi, A. G.; De Montis, A.; Scintu, F.; Putzolu, M.; La Colla, P. Dihydro(alkylthio) (naphthylmethyl)oxopyrimidines: Novel Non- Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series. J. Med. Chem., 1997, 40, 1447-1454.
77. Kulikowski, T. Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review. Pharm World Sci., 1994, 16, 127-138.
78. Zechel, C.; Backfisch, G.; Delzer, J.; Geneste, H.; Graef, C.; Hornberger, W.; Kling, A.; Lange, U. E. W.; Lauterbach, A.; Seitz, W.; Subkowski, T. J. Highly potent and selective αVβ3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4- amino-1H-pyrimidin-2-ones. Biorg. Med. Chem. Lett., 2003, 13, 165-169.
79. Hamper, B. C.; Kesselring, A. S.; Chott, R. C.; Yang, S. Parallel Solid-Phase Synthesis and High-Throughput 1H NMR Evaluation of a 96-Member 1, 2, 4-Trisubstituted-pyrimidin-6-one-5-carboxylic Acid Library. J. Comb. Chem., 2009, 11, 469-480.
80. Zhu, J.; Pottorf, R. S.; Player, M. R. Solid-phase synthesis of 4- biaryl-piperidine-4-carboxamides. Tetrahedron Lett., 2006, 47, 7267-7270.
81. Dankwardt, S. M.; Newman, S. R.; Krstenansky, J. L. Solid phase synthesis of aryl and benzylpiperazines and their application in combinatorial chemistry. Tetrahedron Lett., 1995, 36, 4923-4926.
82. Badarau, A.; Llinás, A.; Laws, A. P.; Damblon, C.; Page, M. I. Inhibitors of metallo-beta-lactamase generated from beta-lactam antibiotics. Biochemistry, 2005, 44, 8578-8589.
83. Park, H.; Merz, K. M. Force Field Design and Molecular Dynamics Simulations of the Carbapenem and Cephamycin-Resistant Dinuclear Zinc Metallo-β-lactamase from Bacteroides fragilis and Its Complex with a Biphenyl Tetrazole Inhibitor. J. Med. Chem., 2005, 48, 1630-1637.
84. Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudinière, R. F. New 4-Point Pharmacophore Method for Molecular Similarity and Diversity Applications: Overview of the Method and Applications, Including a Novel Approach to the Design of Combinatorial Libraries Containing Privileged Substructures. J. Med. Chem., 1999, 42, 3251-3264.
85. Yoo, S.-E.; Seo, J.-S.; Yi, K.-Y.; Gong, Y.-D. Solid phase synthesis of biphenyltetrazole derivatives. Tetrahedron Lett., 1997, 38, 1203- 1206.
86. Kivrakidou, O.; Brase, S.; Hulshorst, F.; Griebenow, N. Solid- Phase Synthesis of 5-Biphenyl-2-yl-1H-tetrazoles. Org. Lett., 2004, 6, 1143-1146.
87. Campos, K. R.; Woo, J. C. S.; Lee, S.; Tillyer R. D. A General Synthesis of Substituted Indoles from Cyclic Enol Ethers and Enol Lactones. Org. Lett., 2004, 6, 79-82.
88. Heinelt, U.; Herok, S.; Matter, H.; Wildgoose, P. Solid-phase optimisation of achiral amidinobenzyl indoles as potent and selective factor Xa inhibitors. Bioorg. Med. Chem. Lett., 2001, 11, 227-230.
89. Yun, W.; Mohan, R. Heck reaction on solid support: synthesis of indole analogs. Tetrahedron Lett., 1996, 37, 7189-7192.
90. Fagnola, M. C.; Candiani, I.; Visentin, G.; Cabri, W.; Zarini, F.; Mongelli, N.; Bedeschi, A. Solid-phase synthesis of indoles using the palladium-catalysed coupling of alkynes with iodoaniline derivatives. Tetrahedron Lett., 1997, 38, 2307-2310.
91. Stephensen, H.; Zaragoza, F. Solid-phase synthesis of Nhydroxyindoles and benzo [c]isoxazoles by C-arylation of substituted acetonitriles and 1, 3-dicarbonyl compounds with polystyrene-bound aryl fluorides. Tetrahedron Lett., 1999, 40, 5799-5802.
92. Collini, M. D.; Ellingboe, J. W. The Solid Phase Synthesis of Tri- Substituted Indoles. Tetrahedron Lett., 1997, 38, 7963-7966.
93. Ketcha, D. M.; Wilsonb, L. J.; Portlockb, D. E. The solid-phase Nenitzescu indole synthesis. Tetrahedron Lett., 2000, 41, 6253- 6257.
94. Cheng, Y.; Chapman, K. T. Solid phase synthesis of spiroindoline. Tetrahedron Lett., 1997, 38, 1497-1500.
95. Collin, G.; Höke, H. Quinoline and Isoquinoline. Ullmann's Encyclopedia of Industrial Chemistry; 15 Jun 2000.
96. O'Loughlin, E. J.; Kehrmeyer, S. R.; Sims, G. K. Isolation, characterization, and substrate utilization of a quinoline-degrading bacterium. International Biodeterioration and Biodegradation, 1996, 38, 107-118.
97. Mayer, J. P.; Lewis, G. S.; McGee, C.; Danute, B.-D. Solid-phase synthesis of benzimidazoles. Tetrahedron Lett., 1998, 39, 6655- 6658.
98. Tumelty, D.; Schwarz, M. K.; Needels, M. C. Solid-phase synthesis of substituted 1-phenyl-2-aminomethyl-benzimidazoles and 1- phenyl-2-thiomethyl- benzimidazoles. Tetrahedron Lett., 1998, 39, 7467-7470.
99. Huang, W.; Searborough, R. M. A new "traceless" solid-phase synthesis strategy: Synthesis of a benzimidazole library. Tetrahedron Lett., 1999, 40, 2665-2668.
100. Kusumi, T.; Ooi, T.; Walchi, M. R.; Kakisawa, H. Structure of the novel antibiotics boxazomycins A, B, and C. J. Am. Chem. Soc., 1988, 110, 2954-2958.
101. Suto, M. J.; Turner, W. R. Synthesis of Boxazomycin B and related analogs. Tetrahedron Lett., 1995, 36, 7213-7216.
102. Chaney, M. O.; Demarco, P. V.; Jones, N. D.; Occolowitz, J. L. Structure of A23187, a divalent cation ionophore. J. Am. Chem. Soc., 1974, 96, 1932-1933.
103. David, L.; Dergomard, A. Production by controlled biosynthesis of a novel ionophore antibiotic, cezomycin (demethylamino A23187). J. Antibiot., 1982, 35, 1409-1411.
104. Westly, J. W.; Liu, J. W.; Blount, J. F.; Sello, L. H.; Troupe, N.; Miller, P. A. Isolation and characterization of a novel polyether antibiotic of the pyrrolether class, antibiotic X- 14885A. J. Antibiot., 1983, 36, 1275-1278.
105. Haugwitz, R. D.; Maurer, B. V.; Jacobs, G. A.; Narayanan, V. L.; Cruthers, L. R.; Szanto, J. Antiparasitic agents. 3. Synthesis and anthelmintic activities of novel 2-pyridinyl-5- isothiocyanatobenzimidazoles. J. Med. Chem., 1979, 22, 1113- 1118.
106. Haugwitz, R. D.; Angel, R. G.; Jacobs, G. A.; Maurer, B. V.; Narayanan, V. L.; Cruthers, L. R.; Szanto, J. Antiparasitic agents. 5. Synthesis and anthelmintic activities of novel 2- heteroaromatic-substituted isothiocyanatobenzoxazoles and -benzothiazoles. J. Med. Chem., 1982, 25, 969-974.
107. Dunwell, D. W.; Evans, D.; Hicks, T. A.; Cashin, C. H.; Kitchen, A. 2-Aryl-5-benzoxazolealkanoic acid derivatives with notable antiinflammatory activity. J. Med. Chem., 1975, 18, 53-58.
108. Dunwell, D. W.; Evans, D.; Hicks, T. A. Synthesis and antiinflammatory activity of some 2-heteroaryl-alpha-methyl-5- benzoxazoleacetic acids. J. Med. Chem., 1975, 18, 1158-1159.
109. Evans, D.; Smith, C. E.; Williamson, W. R. N. Synthesis and antiinflammatory activity of some 2-substituted 4- and 7- benzoxazoleacetic and alpha-methylacetic acids. J. Med. Chem., 1977, 20, 169-171.
110. Dunwell, D. W.; Evans, D. Synthesis and antiinflammatory activity of some 2-aryl-6-benzoxazoleacetic acid derivatives. J. Med. Chem., 1977, 20, 797-801.
111. Edwards, P. D.; Meyer, E. F.; Vijahalakshmi, J.; Tuthill, P. A.; Andisik, D. A.; Gomes, B.; Strimpler, A. Design, synthesis, and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl alpha-ketobenzoxazoles, and the x-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac- Ala-Pro-Val-2-benzoxazole. J. Am. Chem. Soc., 1992, 114, 1854- 1863.
112. Edwards, P. D.; Wolanin, D. J.; Andisik, D. W.; Davis, M. W. Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 2. Effect of varying the heterocyclic ring on in vitro potency. J. Med. Chem., 1995, 38, 76-85.
113. Edwards, P. D.; Zottola, M. A.; Davis, M.; Williams, J.; Tuthill, P. A. Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase. 3 In vitro and in vivo potency of a series of peptidyl alpha- ketobenzoxazoles. J. Med. Chem., 1995, 38, 3972-3982.
114. Katsura, Y.; Nishino, S.; Inoue, Y.; Tomoi, M.; Takasugi, H. Studies on antiulcer drugs. II. Synthesis and antiulcer activities of imidazo [1, 2-alpha]pyridinyl-2-alkylaminobenzoxazoles and 5, 6, 7, 8-tetrahydroimidazo [1, 2-alpha]pyridinyl derivatives. Chem Pharm Bull., 1992, 40, 371-380.
115. Katsura, Y.; Nishino, S.; Inoue, Y.; Tomoi, M.; Itoh, H.; Takasugi, H. Studies on antiulcer drugs. III. Synthesis and antiulcer activities of imidazo [1, 2- A]pyridinylethylbenzoxazoles and related compounds. A novel class of histamine H2-receptor antagonists. Chem Pharm Bull., 1992, 40, 1424-1438.
116. 3 Receptor Partial Agonist for Treatment of Diarrhea- Predominant Irritable Bowel Syndrome. J. Med. Chem., 2005, 48, 7075-7079.
117. McKee, L. M.; Kerwin, S. M. Synthesis, metal ion binding, and biological evaluation of new anticancer 2-(2'- hydroxyphenyl)benzoxazole analogs of UK-1. Bioorg. Med. Chem., 2008, 16, 1775-1783.
118. Fengjiang, W.; James, R. H. Solid-phase synthesis of benzoxazoles via mitsunobu reaction. Tetrahedron Lett., 1997, 38, 6529-6532.
119. Beebe, X.; Wodka, D.; Sowin, T. J. Solid-Phase Synthesis of Benzoxazoles from 3-Nitrotyrosine. J. Comb. Chem., 2001, 3, 360- 366.
120. Hwang, J. Y., Gong, Y. D. Solid-Phase Synthesis of the 2- Aminobenzoxazole Library Using Thioether Linkage as the Safety- Catch Linker. J. Comb. Chem., 2006, 8, 297-303.
121. Hioki, H.; Matsushita, K.; Kubo, M.; Kodama, M. Combinatorial Synthesis of Benzothiazoles and Benzimidazoles Using a Traceless Aniline Linker. J. Comb. Chem., 2006, 8, 462-463.
122. Macro, R.; Sara, S.; Maurizio, B. A one-pot, two-step microwaveassisted synthesis of highly functionalized benzoxazoles using solid-supported reagents (SSRs). Tetrahedron Lett., 2008, 49, 4464-4466.
123. Veseley, J,; Havlicek, L.; Strnad, M.; Blow, J. J.; Donella- Deana, A.; Pinna, L.; Letham, D. S.; Kato, J.-Y.; Detivaud, L.; Leclerc, S.; Meijer, L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem., 1994, 224, 771-786.
124. De Azevedo, W. F.; Leclerc, S.; Meijer, L., Havlicek, L.; Strnad, M.; Kim, S. H. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur. J. Biochem., 1997, 243, 518-524.
125. Legraverend, M.; Ludwig, O.; Bisagni, E.; Leclerc, S.; Meijer, L.; Giocanti, N.; Sadri, R, Favaudon, V. Synthesis and in vitro evaluation of novel 2, 6, 9-trisubstituted purines acting as cyclin-dependent kinase inhibitors. Bioorg. Med. Chem., 1999, 7, 1281-1293.
126. Sielecki, T. M.; Boylan, J. F.; Benfield, P. A., Trainor, G. L. Cyclindependent kinase inhibitors: useful targets in cell cycle regulation. J. Med. Chem., 2000, 43, 1-18.
127. Dhainaut, A.; Regnier, G,; Tizot, A.; Pierre, A.; Leonce, S.; Guilbaud, N.; Kraus-Berthier, L.; Atassi, G. New Purines and Purine Analogs as Modulators of Multidrug Resistance. J. Med. Chem., 1996, 39, 4099-4108.
128. Raffaella, D. L.; Ian, H. G.; Christopher, D. F. Solid Phase Synthesis of Purines from Pyrimidines. J. Comb. Chem., 2000, 2, 249-253.
129. Vankova, B.; Hlavac, J.; Soural, M. Solid-Phase Synthesis of Highly Diverse Purine-Hydroxyquinolinone Bisheterocycles. J. Comb. Chem., 2010, 12, 890-894.
130. Kiselyov, A. S.; Armstrong, R. W. Solid Support Synthesis of Tetrahydroquinolines via the Grieco Three Component Condensation. Tetrahedron Lett., 1997, 38, 6163-6166.
131. 3. Tetrahedron, 1998, 54, 5089- 5096.
132. Kiselyov, A. S.; Smith, L.; Virgilio, A.; Armstrong, R. W. Immobilized aldehydes and olefins in the solid support synthesis of tetrahydroquinolines via a three component condensation. Tetrahedron, 1998, 54, 7987-7996.
133. Zhang, D. W.; Kiselyov, A. S. A Solid-Phase Approach to Tetrahydrochromano [4, 3-b]quinolines. Synlett, 2001, 1173-1175.
134. Wang, Y.; Huang, T. N. Solid-phase synthesis of heterocycles via palladium-catalyzed annulations. Tetrahedron Lett., 1998, 39, 9605-9608.
135. Plosker, G. L.; Sorkin, E. M. Quinapril: A Reappraisal of its Pharmacology and Therapeutic Efficacy in Cardiovascular Disorders. Drugs, 1994, 48, 227-252.
136. Brogden, R. N.; Heel, R. C.; Speight, T. M.; Avery, G. S. Nomifensine: A Review of its Pharmacological Properties and Therapeutic Efficacy in Depressive Illness. Drugs, 1979, 18, 1-24.
137. Lane, J. W.; Estevezc, A.; Mortarac, K.; Callanc, O.; Spencerc, J. R.; Williams, R. M. Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G. Bioorg. Med. Chem. Lett., 2006, 16, 3180-3183.
138. Meutermans, W. D. F.; Alewood, P. F. The solid phase synthesis of dihydro- and tetrahydroisoquinolines. Tetrahedron Lett., 1995, 36, 7709-7712.
139. Rolfing, K.; Thiel, M.; Kunzer, H. 1, 2, 6-Trisubstituted Tetrahydroisoquinoline Derivatives by Solid-Phase Synthesis. Synlett, 1996, 1036-1038.
140. Hutchins, S. M.; Chapman, K. T. Solid phase synthesis of tetrahydroisoquinolines & tetrahydroimidazopyridines. Tetrahedron Lett., 1996, 37, 4865-4868.
141. Fritzen, E. L.; Brightwell, A. S.; Erickson, L. A.; Romero, D. L. The solid phase synthesis of tetrahydroisoquinolines having cdc25B inhibitory activity. Bioorg. Med. Chem. Lett., 2000, 10, 649-652.
142. Kane, T. R.; Ly, C. Q.; Kelly, D. E.; Dener, J. M. Solid-Phase Synthesis of 1, 2, 3, 4-Tetrahydroisoquinoline Derivatives Employing Support-Bound Tyrosine Esters in the Pictet-Spengler Reaction. J. Comb. Chem., 2004, 6, 564-572.
143. Brown, H. C.; in Baude, E. A. and Nachod, F. C., Determination of Organic Structures by Physical Methods. Academic Press, New York, 1955, Chapter 14.
144. O'Loughlin, E. J.; Kehrmeyer, S. R.; Sims, G. K. Isolation, characterization, and substrate utilization of a quinoline-degrading bacterium. International Biodeterioration and Biodegradation, 1996, 38, 107-118.
145. Ruhland, I. T.; Kiinzer, H. Structurally diverse 2, 6-disubstituted quinoline derivatives by solid-phase synthesis. Tetrahedron Lett., 1996, 37, 2757-2760.
146. Gopalsamy, A.; Pallai, P. V. Combinatorial synthesis of heterocycles: Solid phase synthesis of 2-arylquinoline-4-carboxylic acid derivatives. Tetrahedron Lett., 1997, 38, 907-910.
147. Calum, M.; Richard, C. H.; Dieter, W. H. Novel Functionalized Titanium(IV) Benzylidenes for the Traceless Solid-Phase Synthesis of Indoles. Org. Lett., 2002, 4, 75-78.
148. Ciardiello, F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs, 2000, 60, 25-32.
149. Tsou, H. R.; Mamuya, N.; Johnson, B. D.; Reich, M. F.; Gruber, B. C.; Ye, F.; Nilakantan, R.; Shen, R.; Discafani, C.; DeBlanc, R.; Davis, R.; Koehn, F. E.; Greenberger, L. M.; Wang, Y. F.; Wissner, A. 6- Substituted-4-(3- bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinases with Enhanced Antitumor Activity. J. Med. Chem., 2001, 44, 2719-2734.
150. Smaill, J. B.; Rewcastle, G. W.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Showalter, H. D.; Vincent, P. W.; Elliott, W. L.; Denny, W. A. Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazolineand 4-(Phenylamino)pyrido [3, 2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. J. Med. Chem., 2000, 43, 1380-1397.
151. Corbett, J. W.; Ko, S. S.; Rodgers, J. D.; Gearhart, L. A.; Magnus, N. A.; Bacheler, L. T.; Diamond, S.; Je.rey, S.; Klabe, R. M.; Cordova, B. C.; Garber, S.; Logue, K.; Trainor, G. L.; Anderson, P. S.; Erickson-Viitanen, S. K. Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors. J. Med. Chem., 2000, 43, 2019- 2030.
152. Kung, P. P.; Casper, M. D.; Cook, K. L.; Wilson-Lingardo, L.; Risen, L. M.; Vickers, T. A.; Ranken, R.; Blyn, L. B.; Wyatt, J. R.; Cook, P. D.; Ecker, D. J. Structure-Activity Relationships of Novel 2-Substituted Quinazoline Antibacterial Agents. J. Med. Chem., 1999, 42, 4705-4713.
153. Rotella, D. P.; Sun, Z.; Zhu, Y.; Krupinski, J.; Pongrac, R.; Seliger, L.; Normandin, D.; Macor, J. E. Optimization of Substituted N-3- Benzylimidazoquinazolinone Sulfonamides as Potent and Selective PDE5 Inhibitors. J. Med. Chem., 2000, 43, 5037-5043.
154. 3 Receptor. J. Med. Chem., 2000, 43, 2227-2238.
155. Fulton, B.; Wagsta., A. J.; McTavish, D. Trimetrexate: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Treatment of Pneumocystis carinii Pneumonia. Drugs, 1995, 49, 563-576.
156. Spencer, C. M.; Brogden, R. N. Anagrelide: A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in the Treatment of Thrombocythaemia. Drugs, 1994, 47, 809-822.
157. Pescatore, S. L.; Lindley, C. Anagrelide: a novel agent for the treatment
158. Bolognesi, M. L.; Budriesi, R.; Chiarini, A.; Poggesi, E.; Leonardi, A.; Melchiorre, C. Design, Synthesis, and Biological Activity of Prazosin-Related Antagonists. Role of the Piperazine and Furan Units of Prazosin on the Selectivity for α1-Adrenoreceptor Subtypes. J. Med. Chem., 1998, 41, 4844-4853.
159. Brogden, R. N.; Sorkin, E. M. Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease. Drugs, 1990, 40, 903-949.
160. Wang, F.; Hauske, J. R. Solid-phase synthesis of 3, 4- dihydroquinazoline. Tetrahedron Lett., 1997, 38, 8651-8654.
161. Cobb, J. M.; Fiorini, M. T.; Goddard, C. R.; Theoclitou, M. E.; Abell, C. A decarboxylative traceless linker approach for the solid phase synthesis of quinazolines. Tetrahedron Lett., 1999, 40, 1045- 1048.
162. Zhang, J.; Barker, J.; Boliang, L.; Saneii, H. Solid-phase synthesis of 3, 4-dihydroquinazoline derivatives. Tetrahedron Lett., 2001, 42, 8405-8408.
163. Makino, S.; Suzuki, N.; Nakanishi, E.; Tsuji, T. Efficient solidphase synthesis of quinazoline-2-thioxo-4-ones with SynPhase™ lanterns. Tetrahedron Lett., 2000, 41, 8333-8337.
164. Makino, S.; Suzuki, N.; Nakanishi, E.; Tsuji, T. Solid-phase Synthesis of Quinazoline-2, 4-diones Using SNAr Reaction. Synlett, 2001, 333-336.
165. Makino, S.; Nakanishi, E.; Tsuji, T. Solid-phase synthesis of 1, 3- disubstituted 2-thioxoquinazoline-4-ones using SNAr reaction. Tetrahedron Lett., 2001, 42, 1749-1752.
166. Srivastava, G. K.; Kesarwani, A. P.; Grover, R. K.; Srinivasan, T.; Roy, R.; Kundu, B. Solid Phase Synthesis of 2-Aminoquinazoline- Based Compounds. J. Comb. Chem., 2003, 5, 769-774.
167. Grover, R.; Kesarwani, A. P.; Srivastava, G. K.; Kundu, B.; Roy, R. Base catalyzed intramolecular transamidation of 2- aminoquinazoline derivatives on solid phase. Tetrahedron, 2005, 61, 5011-5018.
168. Cerecetto, H.; Di Maio, R.; Gonzalez, M.; Risso, M.; Saenz, P.; Seoane, G.; Denicola, A.; Peluffo, G.; Quijano, C.; Olea-Azar, C. 1, 2, 5-Oxadiazole N-Oxide Derivatives and Related Compounds as Potential Antitrypanosomal Drugs: Structure-Activity Relationships. J. Med. Chem., 1999, 42, 1941-1950.
169. Jacobsen, E. J.; Stelzer, L. S.; TenBrink, R. E.; Belonga, K. L.; Carter, D. B.; Im, H. K.; Im, W. B.; Sethy, V. H.; Tang, A. H.; Von Voigtlander, P. F.; Petke, J. D.; Zhong, W. Z.; Mickelson, J. W. Piperazine Imidazo [1, 5-a]quinoxaline Ureas as High-Affinity GABAA Ligands of Dual Functionality. J. Med. Chem., 1999, 42, 1123-1144.
170. Kim, K. S.; Qian, L.; Bird, J. E.; Dickinson, K. E.; Moreland, S.; Schaeffer, T. R.; Waldron, T. L.; Delaney, C. L.; Weller, H. N.; Miller, A. V. Quinoxaline N-oxide containing potent angiotensin II receptor antagonists: synthesis, biological properties, and structureactivity relationships. J. Med. Chem., 1993, 36, 2335-2342.
171. Sarges, R.; Howard, H. R.; Browne, R. G.; Lebel, L. A.; Seymour, P. A.; Koe, B. K. 4-Amino [1, 2, 4]triazolo [4, 3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. J. Med. Chem., 1990, 33, 2240-2254.
172. Hazeldine, S. T.; Polin, L.; Kushner, J.; Paluch, J.; White, K.; Edelstein, M.; Palomino, E.; Corbett, T. H.; Horwitz, J. P. Design, Synthesis, and Biological Evaluation of Analogues of the Antitumor Agent, 2-{4- [(7-Chloro-2-quinoxalinyl)oxy]phenoxy} propionic Acid (XK469). J. Med. Chem., 2001, 44, 1758-1776.
173. Lee, J.; Murray, W. V.; Rivero, R. A. Solid Phase Synthesis of 3, 4- Disubstituted-7-carbamoyl-1, 2, 3, 4-tetrahydroquinoxalin-2-ones. J. Org. Chem., 1997, 62, 3874-3879.
174. Morales, G. A.; Corbett, J. W.; Degrado, W. F. Solid-Phase Synthesis of Benzopiperazinones. J. Org. Chem., 1998, 63, 1172- 1177.
175. Zaragoza, F.; Stephensen, H. Solid-Phase Synthesis of Substituted 4-Acyl-1, 2, 3, 4-tetrahydroquinoxalin-2-ones. J. Org. Chem., 1999, 64, 2555-2557.
176. Atrash, B.; Bradley, M.; Kobylecki, R.; Cowell, D.; Reader, J. Revolutionizing Resin Handling for Combinatorial Synthesis. Angew. Chem., Int. Ed. Engl., 2001, 113, 964-967.
177. Nefzi, A.; Giulianotti, M. A.; Houghten, R. A. Solid-phase synthesis of branched thiohydantoin benzimidazolinethiones and branched thiohydantoin tetrahydroquinoxalinediones. Tetrahedron Lett., 2000, 41, 2283-2287.
178. Mazurov, A. Solid phase synthesis of 5, 6, 7, 8-tetrahydro-1Himidazo [ 4, 5-g]quinoxalin-6-ones. Tetrahedron Lett., 2000, 41, 7- 10.
179. Krchnak, V.; Szabo, L.; Vagner, J. A solid phase traceless synthesis of quinoxalinones. Tetrahedron Lett., 2000, 41, 2835-2838.
180. Krchnak, V.; Smith, J.; Vagner, J. A solid-phase traceless synthesis of tetrahydroquinoxalines. Tetrahedron Lett., 2001, 42, 2443-2446.
181. Wu, Z.; Ede, N. J. Solid-phase synthesis of quinoxalines on SynPhase™ Lanterns. Tetrahedron Lett., 2001, 42, 8115-8118.
182. Seth, D.; Xiaobing, W.; Kit, S. L.; Mark J. K. Solid-phase synthesis of quinoxaline, thiazine, and oxazine analogs through a benzyne intermediate. Tetrahedron Lett., 2005, 46, 7443-7446.
183. Neagoie, C.; Krchnak, V. Piperazine Amide Linker for Cyclative Cleavage from Solid Support: Traceless Synthesis of Dihydroquinoxalin-2-ones. Comb. Sci., 2012, 14, 399-402.
184. Michael, J. P. Quinoline, quinazoline and acridone alkaloids. Nat. Prod. Rep., 2004, 21, 650-668.
185. Johne, S. In Rodd's Chemistry of Carbon Compounds; Ansell, M. F., Ed.; Supplements to the 2nd ed.; Elsevier: Amsterdam, 1995; IV 1/2, 223.
186. D'yakonov, A. L.; Telezhenetskaya, M. V. Quinazoline alkaloids in nature. Chem. Nat. Comp., 1997, 33, 221-267.
187. Chen, K.; Aowad, A. F.; Adelstein, S. J.; Kassis, A. I. Molecular- Docking-Guided Design, Synthesis, and Biologic Evaluation of Radioiodinated Quinazolinone Prodrugs. J. Med. Chem., 2007, 50, 663-673.
188. Ogawa, N.; Yoshida, T.; Aratani, T.; Koshinaka, E.; Kato, H.; Ito, Y. Synthesis and histamine H2-antagonist activity of 4- quinazolinone derivatives. Chem. Pharm. Bull., 1988, 36, 2955- 2967.
189. McNamara, D. J.; Berman, E. M.; Fry, D. W.; Werbel, L. M. Potent inhibition of thymidylate synthase by two series of nonclassical quinazolines. J. Med. Chem., 1998, 33, 2045-2051.
190. Levin, J. I.; Fanshawe, W. J.; Epstein, J. W.; Beer, B.; Bartus, R. T.; Dean, R. L. Synthesis and activity in cognition-related tests of novel 2-benzoylamino-4-oxoquinazolines. Bioorg. Med. Chem. Lett., 1992, 2, 349-352.
191. Chao, Q.; Deng, L.; Shih, H.; Leoni, L. M.; Genini, D.; Carson, D. A.; Cottam, H. B. Substituted Isoquinolines and Quinazolines as Potential Antiinflammatory Agents. Synthesis and Biological Evaluation of Inhibitors of Tumor Necrosis Factor α. J. Med. Chem., 1999, 42, 3860-3873.
192. Mayer, J. M.; Lewis, G. S.; Curtis, M. J. Solid phase synthesis of quinazolinones. Tetrahedron Lett., 1997, 38, 8445-8448.
193. Villalgordo, J. M.; Orbrencht, D.; Chucholowsky, A. Solid-Phase Synthesis of 3H-Quinazolin-4-ones Based on an Aza Wittig- Mediated annulation Strategy. Synlett, 1998, 1405-1407.
194. Yu, Y.; Ostresh, J. M.; Houghten, R. A. A Traceless Approach for the Parallel Solid-Phase Synthesis of 2-(Arylamino)quinazolinones. J. Org. Chem., 2002, 67, 5831-5834.
195. Kesarwarni, A. P.; Srivastava, G. K.; Rastogi, S. K.; Kundu, B. Solid-phase synthesis of quinazolin-4(3H)-ones with three-point diversity. Tetrahedron Lett., 2002, 43, 5579-5581.
196. Gopalsamy, A.; Yang, H. Combinatorial Synthesis of Heterocycles: Solid-Phase Synthesis of 2-Amino-4(1H)-quinazolinone Derivatives. J. Comb. Chem., 2000, 2, 378-381.
197. Yang, R.-Y.; Kaplan, A. A concise and efficient solid-phase synthesis of 2-amino-4(3H)-quinazolinones. Tetrahedron Lett., 2000, 41, 7005-7008.
198. Zhang, W.; Mayer, J. P.; Hall, S. E.; Weigel, J. A. A Polymer- Bound Iminophosphorane Approach for the Synthesis of Quinazolines. J. Comb. Chem., 2001, 3, 255-256.
199. Kundu, B.; Partani, P.; Duggineni, S.; Sawant, D. Solid-Phase Synthesis of 2-Aminoquinazolinone Derivatives with Two- and Three-Point Diversity. J. Comb. Chem., 2005, 7, 909-915.
200. Jonathan, R. T.; Davidson, M. D. Pharmacotherapy of generalized anxiety disorder. J. Clin. Psychiatry, 2001, 62, 46-50.
201. McCall, W. V. A psychiatric perspective on insomnia. J. Clin. Psychiatry, 2001, 62, 27-32.
202. Hanley, D. F.; Pozo, M. Treatment of status epilepticus with midazolam in the critical care setting. Int. J. Clin. Pract., 2000, 54, 30-35.
203. Robarge, K. D.; Dina, M. S.; Somers, T. C.; Lee, A.; Rawson, T. E.; Olivero, A. G.; Tischler, M. H.; Webb, R. R.; Weese, K. J.; Aliagas, I.; Blackburn, B. K. Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists. Bioorg. Med. Chem., 1998, 6, 2345-2381.
204. Keenan, R. M.; Callahan, J. F.; Samanen, J. M.; Bondinell, W. E.; Calvo, R. R.; Chen, L.; DeBrosse, C.; Eggleston, D. S.; Haltiwanger, R. C.; Hwang, S. M.; Jakas, D. R.; Ku, T. W.; Miller, W. H.; Newlander, K. A.; Nichols, A.; Parker, M. F.; Southhall, L. S.; Uzinskas, I.; Vasko-Moser, J. A.; Venslavsky, J. W.; Wong, A. S.; Huffman, W. F. Conformational Preferences in a Benzodiazepine Series of Potent Nonpeptide Fibrinogen Receptor Antagonists. J. Med. Chem., 1999, 42, 545-559.
205. Suzdak, P. D.; Glowa, J. R.; Crawley, J. N.; Schwartz, R. D.; Skolnick, P.; Paul, S. M. A selective imidazobenzodiazepine antagonist of ethanol in the rat. Science, 1986, 234, 1243-1247.
206. Selnick, H. G.; Liverton, N. J.; Baldwin, J. J.; Butcher, J. W.; Claremon, D. A.; Elliott, J. M.; Freidinger, R. M.; King, S. A.; Libby, B. E.; McIntyre, C. J.; Pribush, D. A.; Remy, D. C.; Smith, G. R.; Tebben, A. J.; Jurkiewicz, N. K.; Lynch, J. J.; Salata, J. J.; Sanguinetti, M. C.; Siegl, P. K.; Slaughter, D. E.; Vyas, K. Class III Antiarrhythmic Activity in vivo by Selective Blockade of the Slowly Activating Cardiac Delayed Rectifier Potassium Current IKs by (R)-2-(2, 4- Trifluoromethyl)-N- [2-oxo-5-phenyl- 1-(2, 2, 2- trifluoroethyl)-2, 3-dihydro- 1H-benzo [e] [1, 4]diazepin-3- yl]acetamide. J. Med. Chem., 1997, 40, 3865-3868.
207. Albright, J. D.; Reich, M. F.; De los Santos, E. G.; Dusza, J. P.; Sum, F. W.; Venkatesan, A. M.; Coupet, J.; Chan, P. S.; Ru, X.; Mazandarani, H.; Bailey, T. 5-Fluoro-2-methyl-N- [4-(5Hpyrrolo [ 2, 1-c]- [1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3- chlorophenyl]benzamide (VPA-985): An Orally Active Arginine Vasopressin Antagonist with Selectivity for V2 Receptors. J. Med. Chem., 1998, 41, 2442-2444.
208. Ho, W.; Kukla, M. J.; Breslin, H. J.; Ludovici, D. W.; Grous, P. P.; Diamond, C. J.; Miranda, M.; Rodgers, J. D.; Ho, C. Y.; De Clercq, E.; Pauwels, R.; Andries, K.; Janssen, M. A. C.; Janssen, P. A. Synthesis and Anti-HIV-1 Activity of 4, 5, 6, 7-Tetrahydro-5- methylimidazo [4, 5, 1-jk] [1, 4]benzodiazepin-2(1H)-one (TlBO) Derivatives. J. Med. Chem., 1995, 38, 794-802.
209. Castro, J. L.; Broughton, H. B.; Russell, M. G.; Rathbone, D.; Watt, A. P.; Ball, R. G.; Chapman, K. L.; Patel, S.; Smith, A. J.; Marshall, G. R.; Matassa, V. G. 5-(Piperidin-2-yl)- and 5- (Homopiperidin-2-yl)-1, 4-benzodiazepines: High-Affinity, Basic Ligands for the Cholecystokinin-B Receptor. J. Med. Chem., 1997, 40, 2491-2501.
210. Rahbaek, L.; Breinholt, J. Circumdatins D, E, and F: Further Fungal Benzodiazepine Analogues from Aspergillus ochraceus. J. Nat. Prod., 1999, 62, 904-905.
211. Joshi, B. K.; Gloer, J. B.; Wicklow, D. T.; Dowd, P. F. Sclerotigenin: A New Antiinsectan Benzodiazepine from the Sclerotia of Penicillium sclerotigenum. J. Nat. Prod., 1999, 62, 650-652.
212. Camps, F.; Castells, J.; Font, J.; Pi, J. Organic syntheses with functionalized polymers: IV. Synthesis of 1, 3-dihydro-5-phenyl- 2H-1, 4-benzodiazepin-2-ones. Anales de Química., 1974, 70, 848- 849.
213. Bevacqua, F.; Basso, A.; Gitto, R.; Bradley, M.; Chimirri, A. Solidphase Friedel-Crafts acylation on polystyrene resins-synthesis of antiepiletic 1-aryl-3, 5-dihydro-4H-2, 3-benzodiazepin-4-ones. Tetrahedron Lett., 2001, 42, 7683-7685.
214. Nefzi, A.; Ong, N. A.; Houghten, R. A. Parallel synthesis of 4, 5- dihydro-1H-1, 4-benzodiazepine-2, 3-diones. Tetrahedron Lett., 2001, 42, 5141-5143.
215. Berry, J. M.; Howard, P. W.; Thurston, D. E. Solid-phase synthesis of DNA-interactive pyrrolo [2, 1-c] [1, 4]benzodiazepines. Tetrahedron Lett., 2000, 41, 6171-6174.
216. Lee, J.; Gauthier, D.; Rivero, R. A. Solid-Phase Synthesis of 3, 4, 5- Substituted 1, 5-Benzodiazepin-2-ones. J. Org. Chem., 1999, 64, 3060-3065.
217. Plunkett, M. J.; Ellman, J. A. Solid-Phase Synthesis of Structurally Diverse 1, 4-Benzodiazepine Derivatives Using the Stille Coupling Reaction. J. Am. Chem. Soc., 1995, 117, 3306-3307.
218. Plunkett, M. J.; Ellman, J. A. Germanium and Silicon Linking Strategies for Traceless Solid-Phase Synthesis. J. Org. Chem., 1997, 62, 2885-2893.
219. Schwarz, M. K.; Tumelty, D.; Gallop, M. A. Solid-phase synthesis of 1, 5-benzodiazepin-2-ones. Tetrahedron Lett., 1998, 39, 8397- 8400.
220. Kamal, A.; Reddy, G. S. K.; Raghavan, S. Solid-phase synthesis of pyrrolo [2, 1-c] and benzodiazepine-5, 11-diones. Bioorg. Med. Chem. Lett., 2001, 11, 387-389.
221. Kamal, A.; Reddy, G. S. K.; Reddy, K. L. Efficient reduction of aromatic nitro/azido groups on solid support employing indium: synthesis of pyrrolo [2, 1-c] [1, 4]benzodiazepine-5, 11-diones. Tetrahedron Lett., 2001, 42, 6969-6971.
222. Bhalay, G.; Blaney, P.; Palmer, V. H.; Baxter, A. D. Solid-phase synthesis of diverse tetrahydro-1, 4-benzodiazepine-2-ones. Tetrahedron Lett., 1997, 38, 8375-8378.
223. Boojamra, C. G.; Burow, K. M.; Thompson, L. A.; Ellman, J. A. Solid-Phase Synthesis of 1, 4-Benzodiazepine-2, 5-diones. Library Preparation and Demonstration of Synthesis Generality. J. Org. Chem., 1997, 62, 1240-1256.
224. Kessler, H. Conformation and Biological Activity of Cyclic Peptides. Angew. Chem., Int. Ed. Engl., 1982, 21, 512-523.
225. Wipf, P. Synthetic Studies of Biologically Active Marine Cyclopeptides. Chem. Rev., 1995, 95, 2115-2134.
226. Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gallop, M. A. Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions. J. Med. Chem., 1994, 37, 1385-1401.
227. Lambert, J. N.; Mitchell, J. P.; Roberts, K. D. The synthesis of cyclic peptides. J. Chem. Soc. Perkin Trans. 1, 2001, 471-484.
228. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomere Peptid- Bibliotheken und Peptidmimetika zum Design von selektiven Inhibitoren des αv β3-Integrins für eine neuartige Krebstherapie. Angew Chem, 1997, 109, 1440-1456.
229. Haubner, R.; Finsinger, D.; Kessler, H. Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer Therapy. Angew. Chem. Int. Ed. Engl. 1997, 36, 1374-1389.
230. Kutscher, B.; Bernd, M.; Beckers, T.; Polymeropoulos, E. E.; Engel, J. Chemistry and Molecular Biology in the Search for New LHRH Antagonists. Angew. Chem. Int. Ed. Engl., 1997, 36, 2148-2161.
231. Kates, S. A.; Solé, N. A.; Albericio, F.; Barany, G., Basava, C.; Anantharamaiah, G. M., Eds., Boston, Birkhauser: 1994, 39-58.
232. Solid phase synthesis of cyclic peptides, Peptides: Design, Synthesis and Biological Activity., Kutscher, B.; Bernd, M.; Beckers, T.; Polymeropoulos, E. E.; Engel, J Chemistry and Molecular Biology in the Search for New LHRH Antagonists. Angew. Chem., 1997, 109, 2240-2254.
233. McMurray, J. Solid phase synthesis of a cyclic peptide using fmoc chemistry. Tetrahedron Lett., 1991, 32, 7679-7682.
234. Mihara, H.; Yamabe, S.; Nildome, T.; Aoyagi, H.; Kumagai, H. Efficient preparation of cyclic peptide mixtures by solid phase synthesis and cyclization cleavage with oxime resin. Tetrahedron Lett., 1995, 36, 4837-4840.
235. Richter, L. S.; Tom, J. Y. K.; Brunier, J. P. Peptide-Cyclizations on solid support: A fast and efficient route to small cyclopeptides. Tetrahedron Lett., 1994, 35, 5547-5550.
236. Yang, L.; Moriello, G. Solid phase synthesis of 'head-to-tail' cyclic peptides using a sulfonamide 'safety-catch' linker: the cleavage by cyclization approach. Tetrahedron Lett., 1999, 40, 8197-8200.
237. Rosenbaum, C.; Waldmann, H. Solid phase synthesis of cyclic peptides by oxidative cyclative cleavage of an aryl hydrazide linker-synthesis of stylostatin 1. Tetrahedron Lett., 2001, 42, 5677-5680.
238. Wieland, T.; Lewalter, J.; Birr, C. Subsequent activation of carboxylic derivatives by oxidation or elimination of water; application for cyclizing peptides. Liebigs Ann. Chem., 1970, 740, 31-47.
239. Aimetti, A. A.; Shoemaker, R. K.; Linc, C.-C.; Anseth, K. S. Onresin peptide macrocyclization using thiol-ene click chemistry. Chem. Commun., 2010, 46, 4061-4063.
240. Ingale, S.; Dawson, P. E. On Resin Side-Chain Cyclization of Complex Peptides Using CuAAC. Org. Lett., 2011, 13, 2822-2825.
241. Lee, J. H.; Kim, H.-S.; Lim, H.-S. Design and Facile Solid-Phase Synthesis of Conformationally Constrained Bicyclic Peptoids. Org. Lett., 2011, 13, 5012-5015.